The MarketWatch News Department was not involved in the creation of this content. New Data from SkylineDx Demonstrates Merlin CP-GEP Test's Superior Melanoma Risk Stratification -- New data analysis ...
ROTTERDAM, Netherlands and SAN DIEGO, Calif., Dec. 18, 2025 /PRNewswire/ -- SkylineDx today announced the release of new data from two complementary, peer-reviewed publications that reinforce the ...
New data analysis clarifies misleading benchmarks released by a competitor; separate SkylineDx analysis demonstrates Merlin CP-GEP Test provides stronger metastatic-risk stratification and superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback